Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 11/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 3/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420498 | 1.00 | MAP4K1 (0.42) | MAP4K1PIK3C3TYK2GSK3BGSK3A | |
| SCHEMBL26686481 | 0.88 | PIK3C3 (0.52) | PIK3C3 | |
| SCHEMBL31420490 | 0.88 | PIK3C3 (0.52) | PIK3C3 | |
| SCHEMBL26686694 | 0.87 | PIK3C3 (0.42) | PIK3C3GSK3BNR3C2 | |
| SCHEMBL31420705 | 0.87 | AAK1 (0.44) | PIK3C3CYP3A4 | |
| SCHEMBL26686446 | 0.87 | AAK1 (0.44) | PIK3C3CYP3A4 | |
| SCHEMBL31420510 | 0.86 | PIK3C3 (0.51) | PIK3C3CYP3A4 | |
| SCHEMBL30633291 | 0.86 | PIK3C3 (0.51) | PIK3C3CYP3A4 | |
| SCHEMBL26888164 | 0.86 | PIK3C3 (0.51) | PIK3C3CYP3A4 | |
| SCHEMBL31420562 | 0.85 | PIK3C3 (0.41) | PIK3C3TYK2GSK3BGSK3ABUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | MAP4K1 185/4885PIK3C3 575/4885TYK2 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.